PBH Earnings Date: Nov 5, 2026 (Estimated) — Prestige Consumer Healthcare Inc.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is PBH's next earnings date?
Prestige Consumer Healthcare Inc. (PBH) is expected to report Q2 2027 earnings on Thursday, November 5, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $1.07 on revenue of $329.1M.
How did PBH do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q1 2027), Prestige Consumer Healthcare Inc. posted EPS of $0.98 versus the $0.87 estimate, a beat of 12.6%. Revenue was $265.7M against a $250.1M estimate. The stock's 1-day post-earnings move was +2.7%.
How much does PBH stock move after earnings?
PBH beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.8% (up or down) in the day after earnings.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q1 2027 | 0.87 | 0.98 | +12.64% | $265.7M | ✅ Beat | +2.74% | -1.34% | -0.79% |
| 2026-08-06 | Q2 2026 | 1.46 | 1.53 | +4.79% | $2.38B | ✅ Beat | +2.74% | -1.34% | -0.79% |
| 2026-05-13 | Q4 2026 | 1.40 | 1.23 | -12.14% | $281.6M | ❌ Miss | -11.35% | -8.92% | -7.70% |
| 2026-05-07 | Q1 2026 | 0.85 | 0.83 | -2.35% | $2.05B | ❌ Miss | +0.52% | -4.60% | -13.13% |
| 2026-03-19 | Q4 2025 | 1.35 | 1.29 | -4.44% | $1.90B | ❌ Miss | -1.14% | +0.63% | -4.31% |
| 2026-02-05 | Q3 2026 | 1.16 | 1.14 | -1.72% | $283.4M | ❌ Miss | -2.21% | -1.58% | +0.24% |
| 2025-02-06 | Q3 2025 | 1.16 | 1.22 | +5.17% | $290.3M | ✅ Beat | +14.78% | +10.66% | +16.98% |
| 2024-11-07 | Q2 2025 | 1.08 | 1.09 | +0.93% | $283.8M | ✅ Beat | +3.16% | +6.03% | +8.62% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q1 FY27 · $170.3M total
| Segment | Share | Revenue | YoY | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|
| Gastrointestinal | 36.5% | $62.2M | +7.6% | $69.0M | $68.9M | $57.8M | $64.2M |
| Women's Health | 30.9% | $52.5M | -7.4% | $58.1M | $63.8M | $56.8M | $56.2M |
| Dermatologicals | 19.5% | $33.2M | +10.2% | $30.7M | $29.1M | $30.1M | $35.7M |
| Oral Care | 13.1% | $22.4M | +3.0% | $23.1M | $27.1M | $21.7M | $24.8M |
By region
Q4 FY22 · $266.9M total
| Segment | Share | Revenue | YoY | Q2 FY21 | Q3 FY21 | Q4 FY21 | Q1 FY22 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 82.3% | $219.6M | +10.3% | $203.3M | $197.3M | $199.1M | $226.7M |
| Non-US | 17.7% | $47.4M | +22.5% | $34.1M | $41.5M | $38.7M | $42.5M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.